Seattle, WA, November 14, 2024 / EINPresswire.com /– Healionics Corporation, a developer of synthetic biomaterial-based medical devices, today announced that its STARgraft arteriovenous graft – designed to provide a safer and more reliable means of bloodstream access for kidney failure patients needing dialysis – has been granted Breakthrough Device designation by the FDA.

Read more.